Literature DB >> 14696118

HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors.

Elizabeth Half1, Russell Broaddus, Kathleen D Danenberg, Peter V Danenberg, Gregory D Ayers, Frank A Sinicrope.   

Abstract

The HER-2/neu oncogene encodes a 185 kD protein that is phosphorylated upon ligand binding to other HER/erbB members and regulates cell growth and differentiation. Given that HER-2 receptor blockade can inhibit the growth of colon cancer cell lines and tumor xenografts, we investigated the frequency, localization and phosphorylation status of HER-2 in colon cancer cell lines and in human tumors. Protein expression was analyzed in relation to mRNA levels, HER-2 amplification, and clinicopathological variables. Colon cancer cell lines constitutively expressed HER-2 proteins and none showed HER-2 amplification by fluorescence in situ hybridization. Cell fractionation and immunoblotting showed HER-2 in both the membrane and cytosolic compartments. Primary colorectal carcinomas (n = 96) and their metastases (n = 25) were examined by immunohistochemistry. Strong membrane HER-2 staining was detected in 5 (5%) of primaries and in 3 (12%) metastases (p = 0.36). Membrane but not cytoplasmic localization was strongly associated with HER-2 gene amplification (p = 0.007). Cytoplasmic HER-2 staining was found in 61 (63.5%) of primary tumors and localization was confirmed by immunoelectron microscopy that also showed plasma membrane HER-2. Using real-time quantitative RT-PCR, HER-2 mRNA was increased in tumors with membrane compared to cytoplasmic staining (r = 0.66, p = 0.001). Cytoplasmic HER-2 was associated with tumor differentiation (p = 0.018), but not other clinicopathological variables. By immunoblotting, heterogeneity was seen in HER-2 levels with downregulation in 4 of 7 tumors relative to normal epithelia that uniformly expressed HER-2. Phosphorylated HER-2 was detected in approximately 50% of tumors and in normal mucosa. In conclusion, HER-2 is expressed constitutively in colon cancer cell lines and demonstrates relatively distinct localization patterns in human tumors. Strong membrane immunoreactivity is associated with high levels of HER-2 mRNA and gene amplification whereas cytoplasmic HER-2 is detected frequently and seems to be a marker of tumor differentiation. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14696118     DOI: 10.1002/ijc.11599

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  30 in total

Review 1.  The Mediterranean diet: effects on proteins that mediate fatty acid metabolism in the colon.

Authors:  Zora Djuric
Journal:  Nutr Rev       Date:  2011-12       Impact factor: 7.110

2.  Over-expression of Her-2 in colorectal cancer tissue, but not in serum, constitutes an independent worse prognostic factor.

Authors:  Sang-Woo Lim; Hye-Ran Kim; Hwan-Young Kim; Jung-Wook Huh; Young-Jin Kim; Jong-Hee Shin; Soon-Pal Suh; Dong-Wook Ryang; Hyeong-Rok Kim; Myung-Geun Shin
Journal:  Cell Oncol (Dordr)       Date:  2013-05-31       Impact factor: 6.730

3.  A simple biological imaging system for detecting viable human circulating tumor cells.

Authors:  Toru Kojima; Yuuri Hashimoto; Yuichi Watanabe; Shunsuke Kagawa; Futoshi Uno; Shinji Kuroda; Hiroshi Tazawa; Satoru Kyo; Hiroyuki Mizuguchi; Yasuo Urata; Noriaki Tanaka; Toshiyoshi Fujiwara
Journal:  J Clin Invest       Date:  2009-10       Impact factor: 14.808

4.  Immunohistochemical results of HER2/neu protein expression assessed by rabbit monoclonal antibodies SP3 and 4B5 in colorectal carcinomas.

Authors:  Zhangjuan Song; Yan Deng; Kangmin Zhuang; Aimin Li; Side Liu
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

5.  MUC4 expression is a novel prognostic factor in patients with invasive ductal carcinoma of the pancreas.

Authors:  M Saitou; M Goto; M Horinouchi; S Tamada; K Nagata; T Hamada; M Osako; S Takao; S K Batra; T Aikou; K Imai; S Yonezawa
Journal:  J Clin Pathol       Date:  2005-08       Impact factor: 3.411

Review 6.  Colon cancer and the immune system: the role of tumor invading T cells.

Authors:  Maximilian Waldner; Carl-C Schimanski; Markus-F Neurath
Journal:  World J Gastroenterol       Date:  2006-12-07       Impact factor: 5.742

7.  EGFR and HER2 inhibition in pancreatic cancer.

Authors:  Naomi Walsh; Susan Kennedy; AnneMarie Larkin; Brendan Corkery; Lorraine O'Driscoll; Martin Clynes; John Crown; Norma O'Donovan
Journal:  Invest New Drugs       Date:  2012-10-18       Impact factor: 3.850

8.  Meprinα transactivates the epidermal growth factor receptor (EGFR) via ligand shedding, thereby enhancing colorectal cancer cell proliferation and migration.

Authors:  Petra Minder; Elke Bayha; Christoph Becker-Pauly; Erwin E Sterchi
Journal:  J Biol Chem       Date:  2012-08-24       Impact factor: 5.157

9.  Frequency of HER2/neu overexpression in adenocarcinoma of the gastrointestinal system.

Authors:  Sadaf Farzand; Tahir Siddique; Kanwal Saba; Mulazim Hussain Bukhari
Journal:  World J Gastroenterol       Date:  2014-05-21       Impact factor: 5.742

10.  Design and Synthesis of Near-Infrared Peptide for in Vivo Molecular Imaging of HER2.

Authors:  Bishnu P Joshi; Juan Zhou; Asha Pant; Xiyu Duan; Quan Zhou; Rork Kuick; Scott R Owens; Henry Appelman; Thomas D Wang
Journal:  Bioconjug Chem       Date:  2015-12-28       Impact factor: 4.774

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.